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studies worldwide. METHODS: We searched Medline, EMBASE, and three other 
Chinese databases from their inception to June 2008. We included case-control and
cohort studies that investigated the association of smoking with lung cancer, and that
provided data on the magnitude of the association. Two reviewers screened the eligibil-
ity, assessed the extent of bias, and extracted data independently. We obtained unad-
justed and adjusted estimates of studies. We pooled the trial data using random-effect 
model and explored the heterogeneity by the pre-speciﬁ ed variables. RESULTS: We 
included 45 (n  71,869), 4 of which were cohort studies (n  48,250) and 41 case-
control studies (cumulative cases: 10,268, and controls: 13,351). Smoking increased 
the risk of lung cancer by 137% (OR 2.37, 95%CI 1.95 to 2.88). Pooling of adjusted 
estimates of in 32 studies showed that the risk of lung cancer was increased by 181% 
(2.81, 2.31 to 3.42). No gender difference was found in the association (15 studies): 
ORs were 3.19 (2.51 to 4.06) in male and 2.98 (2.29 to 3.89) in female (interaction
p  0.1). The risks were statistically different in different type of lung cancer: aden-
carcinoma 1.81 (1.23 to 2.66), squamous cell carcinoma 7.07 (2.34 to 21.38), and
small cell lung cancer 7.98 (4.22 to 15.11). The increased amount of smoking 
increased the risk of lung cancer (coef. 0.27, 0.03 to 0.51). No signiﬁ cant dose-
response was found between the risk of lung cancer and the duration and initiating 
age of smoking. CONCLUSIONS: The association between smoking and lung cancer
has been ascertained in the Chinese population. Pronounced heterogeneity in risks of 
lung cancer was found in different type of lung cancer and amount of smoking.
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OBJECTIVES: Increasing attention has been paid to team-based approaches to the 
management of patients with advanced prostate cancer (PCa). It is not known whether 
the timing of specialist contacts relative to treatment initiation is associated with sur-
vival. This study examines whether patients with visits to a medical oncologist/hema-
tologist (MOH) before treatment have better survival outcomes than those who see a
MOH after treatment begins. METHODS: A retrospective analysis of linked Surveil-
lance, Epidemiology, and Endpoints (SEER) – Medicare data included patients diag-
nosed with Stage IV PCa between 1994 and 2002 (age  65 years) who received 
treatment and a referral. Treatment was deﬁ ned as the receipt of orchiectomy, hormone 
therapy, chemotherapy, or radiation at any time following diagnosis. A referral was 
deﬁ ned as a post-diagnosis visit to an urologist followed by a visit to a MOH. The 
key covariate identiﬁ ed patients referred prior to treatment initiation. Colon cancer – 
speciﬁ c mortality models controlled for potential confounders including demographic, 
clinical, continuity-of-care, and ecological measures. RESULTS: A total of 2075
patients with Stage IV PCa met the inclusion criteria. The average age in the sample 
was 75 years and 83% were White. Seven percent of patients visited both specialists 
before receiving treatment. Referral visits prior to the start of treatment were associ-
ated with a reduction in the relative risk of disease – speciﬁ c mortality (HR: 0.7; 0.5 
– 0.9, p  0.02) in the full sample and in a propensity-matched sample (HR: 0.6; 0.4 
– 0.9, p  0.006). CONCLUSIONS: As treatment options for advanced stage PCa
evolve, patients may beneﬁ t from contact with a team of specialists. We ﬁ nd that there 
is a survival beneﬁ t associated with referrals that occur prior to treatment initiation. 
The results suggest that the timing of specialist visits is important for PCa survival. 
Further studies on referral patterns are needed to validate these results.
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OBJECTIVES: Atypical antipsychotics are currently the most frequently prescribed
class of drugs for schizophrenia. These drugs appear to be associated with varying
degrees of metabolic adverse effects. We conducted a retrospective clinical study to
evaluate the adverse metabolic effects of antipsychotic medications in schizophrenic 
patients in Taiwan population. METHODS: This is a retrospective observational 
study. A total of 431 outpatients who were diagnosed with schizophrenia and taken
clozapine or olanzapine or risperidone or haloperidol for more than one year were
included in this study. We excluded those who took other drugs known to affect 
glucose metabolism (including á, â-blockers, thiazide diuretics, phenytoin, valproate,
and corticosteroids), and those who were diagnosed with diabetes mellitus and hyper-
lipidemia at the initial time of study. The changes of blood lipids and fasting blood 
glucose levels noted in the medical records were reviewed and analyzed. RESULTS:
The results indicated that 298 outpatients showed weight gain after 6^8 months of 
medications. 83.3%(60/72) of risperidone-treated patients had experienced signiﬁ cant 
weight gain as compared with 48.8%(40/82) of clozapine and 4% (2/50) haloperidol 
treated patients (p  0.001). The potential risk of increased fasting blood glucose, 
cholesterol, and triglyceride levels for risperidone-treated patients were 50.5 o 4.2%, 
13.9 o 5.6% and 53.8 o 4.2%, respectively. 48 patients need additional drugs to regu-
late the increased metabolic levels, such as atorvastatin for increased triglyceride levels
and glucophage for increased blood glucose level. The extra medications expenditure 
used to regulate the adverse effect was about NT 13 million each year. CONCLU-
SIONS: The atypical antipsychotic drugs can cause adverse metabolic effects. Ameri-
can Diabetes Association (ADA) suggested to monitor patients’ body weight, fasting 
blood glucose, and lipid proﬁ le for those who are prescribed atypical antipsychotics.
Additionally, the diet control and regular exercise should be suggested to patients who
have already been getting weight in the treatment of atypical antipsychotics.
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OBJECTIVES: The aim of this study was to compare the effectiveness and servival
rate of cetuxiamb plus chemotherapy with the traditional chemotherapy alone in the 
treatment of metastatic colorectal cancer.( mCRC). METHODS: This is a retrospective 
observational study which was conducted from January 2004 to December 2008. 
Hospitalized patients diagnosed with mCRC and treated with chemotherapy regimen
of FOLFIRI (irinotecan/ 5-ﬂ uorouracil/ leucovorin) plus cetuximab or patients treated 
with FOLFIRI or FOLFOX (oxaliplatin/5-ﬂ uorouracil/leucovorin) chemotherapy 
regimen alone for a course of 1 year were recruited. The medical records for all 
patients recruited were evaluated by clinical pharmacist. T-test was used for analysis. 
RESULTS: A total of 143 patients were identiﬁ ed. Sixty-ﬁ ve patients were treated with 
FOLFIRI (irinotecan/ 5-ﬂ uorouracil/ leucovorin) plus cetuximab and seventy-eight 
patients were treated with FOLFIRI or FOLFOX alone. The results showed that total 
50 patients treated with FOLFIRI combined with cetuximab were survived about 17.3 
months, survival rate was 64%; whereas, total of 65 patients treated with FOLFIRI
or FOLFOX alone were survived about 12.9 months, survival rate was 41%. By using 
chemotherapy combined with cetuximab, the survival rate increased about 4.4 
momths as compared to the chemogtherapy alone. The difference of survival rate 
between two groups is statistical signiﬁ cant. (p value is 0.018). CONCLUSIONS: The 
preliminary result indicated that chemotherapy plus cetuximab is more effective as
compared to chemotherapy alone for mCRC patients. However, cetuximab is more
expensive target chemotherapeutic drugs in our country, therefore, evaluation on 
direct medical costs of two regimens is indispensable and data will be completed in 
the near future.
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OBJECTIVES: Recommended treatment duration of atrophic vaginitis in postmeno-
pausal women with vaginal estrogen (VE) is currently limited to 6–12 months, the
length of clinical trials conducted to date, due to concerns of potential development
of endometrial carcinoma. In practice, many women use VE longer. This study exam-
ines the association between VE use and risk of endometrial carcinoma over a 3 year 
follow-up period among Medicaid enrollees. METHODS: A retrospective cohort 
study was conducted using North Carolina Medicaid prescription and medical claims 
between January 1998 and December 2007. The study included women ages 18–64 
years with a prescription claim for VE (cream, tablet, and ring forms) or a diagnosis 
of atrophic vaginitis (identiﬁ ed by ICD-9 code 627.3). Demographic factors included
age and race (African American, white, or other). Comorbidity risk adjustment was
determined using the Charlson-Deyo method. Multiple logistic regression was per-
formed to assess the association of VE use and endometrial carcinoma adjusting for 
age, race, and comorbidities. RESULTS: A total of 770 patients prescribed VE (mean
age 50.1 years /8.4) and 881 patients diagnosed with atrophic vaginitis but not 
treated with VE (mean age 49.4 years /9.8) were identiﬁ ed in the database. Ten 
cases of uterine carcinoma were identiﬁ ed among the VE patients; 11 cases among 
women not prescribed VE. Logistic regression results showed no signiﬁ cant difference
in the occurrence of endometrial carcinoma between women on VE therapy and those 
not on VE therapy (OR  1.11, 95%CI: 0.47–2.65, P  0.814). Older age was the 
only signiﬁ cant predictor of uterine carcinoma (OR  1.11, 95%CI: 1.03–1.20, P 
0.008); i.e., for a ten-year increase in age, odds of endometrial carcinoma increased 
by a factor of 2.8. CONCLUSIONS: With three years of follow-up showed no associa-
tion between VE exposure and endometrial carcinoma. Increasing age was found to 
be the only signiﬁ cant risk factor.
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OBJECTIVES: The phase III trial AVOREN demonstrated that BEV  interferon-
alpha2a (IFN) prolongs progression-free survival compared with IFN  placebo in 
patients with untreated mRCC [Escudier, Lancet 2007]. The protocol speciﬁ ed that 
the recommended dose of IFN (9MIU 3x/week) could be lowered to 6 or 3MIU for 
grade q3 adverse events (AEs) attributable to IFN or other investigator-deﬁ ned 
reasons. A retrospective analysis of AVOREN showed that lower-dose (LD) IFN in 
combination with BEV improves tolerability and maintains clinical beneﬁ t [Melichar, 
Ann Oncol 2008]. We report here the costs of managing side effects of BEV  LD IFN 
